To Whom It May Concern

November. 6, 2018

NanoCarrier Co. Ltd.
Ichiro Nakatomi, President & CEO
(Code No. 4571 TSE Mothers)

VB-111: Results of A Phase III Study for rGBM

We are pleased to announce that the abstract of the presentation on the results of the GLOBE study (a phase 3 study of VB-111 in patients with rGBM) at the 23rd SNO (Society for Neuro Oncology) annual meeting has been published. The meeting will be held in New Orleans from November 15 to 18, 2018.

*: https://www.soc-neuro-onc.org/SNO/2018Annual/2018AnnualHome.aspx

Title and presentation date

Results of the GLOBE study: a phase 3, randomized, controlled, double-arm, open-label, multi-center study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma

Cloughesy T, Brenner AJ, Butowski N, Cohen YC, Lowenton-Spier N, Wen P

November 16, 2018, 15:35 – 15:45 (CONCURRENT SESSION 3A)

Abstract

https://academic.oup.com/neuro-oncology/article-abstract/20/suppl_6/vi4/5153615?redirectedFrom=fulltext

Contact: Tetsuhito Matsuyama
Director, CFO and Head of CEO's Office
Phone: 03-3241-0553